english.prescrire.org > Prescrire International > N°167 - January 2016

n°167

January 2016

Issue Contents
Editorial

Free  When major trials mean minor efficacy

p.4
Mirabegron is a case in point

New Products


Liraglutide (Saxenda°) and obesity

p.5-8
Still no satisfactory weight loss drugs

Mirabegron (Betmiga°)

p.8-9
Poorly effective in urge urinary incontinence

Drugs targeting beta-adrenergic receptors: total "selectivity" is elusive

p.9

INN common stem: -begron

p.9

Free  Gestodene + ethinylestradiol (Apleek°)

p.10
No place for a patch containing a third-generation progestin

Free  Repackaging

p.10
Editors' opinion

Cabozantinib (Cometriq°)

p.11-13
In medullary thyroid cancer: more harmful than beneficial, as is vandetanib

Adverse Effects


NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac

p.14-16
Naproxen and low dose ibuprofen are safer

Postmenopausal hormone replacement therapy: ovarian cancer

p.16
1 ovarian cancer per 1000 women exposed to HRT

Trimethoprim during the 3 months before pregnancy: malformations in children

p.17
Malformations due to folic acid depletion

Gliptins, exenatide, liraglutide: "intestinal obstruction"

p.17
Reduced gastrointestinal motility exposes to potentially serious consequences

Reviews


Helicobacter pylori and gastric or duodenal ulcer

p.18-23
First-line empirical treatment in 2015: amoxicillin + clarithromycin + metronidazole

Use a non-invasive test to verify H. pylori eradication

p.21

Bronchiolitis in infants: do not use bronchodilators

p.23
Trials including about 2000 infants showed no measurable impact

Outlook


Electronic prescribing: the risk of errors and adverse effects

p.24-27
Health professionals must remain vigilant

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe